Anklam Extrakt Partners With Catalent To Launch Innovative Softgel Supplement For Dry Eye Discomfort

SOMERSET, N.J. – November 1, 2018 — Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has successfully partnered with Anklam Extrakt GmbH, to develop an innovative softgel formula for people suffering from dry eye discomfort. The product will be launched at the upcoming SupplySide West exhibition, taking place at the Mandalay Bay Hotel, Las Vegas, on Nov. 8–9, 2018.

 Anklam Extrakt’s new product, OPTIBRIGHT™ Softgel, combines its unique blend of 30 mg MaquiBright® maqui berry extract and 450 mg of omega-3 fish oil, with Catalent’s softgel formulation and encapsulation technology. The result is a convenient, once-or-twice daily supplement intended to aid tear formation and provide relief for dry eye discomfort.

 At SupplySide West, Catalent and Anklam Extrakt will host an expert speaking session at 11 a.m. on Thursday, Nov. 8, 2018 at the Exhibition Theatre booth #1381, entitled “Latest Advancements in Nutritional Supplements for Dry Eyes.” The presentation, by Dr. Andrew Myers, Scientific Advisor, Nutritional Softgels, Catalent Pharma Solutions, will discuss the advantages that this product, with its unique formulation of active ingredients, brings to the marketplace.

Mr. Timothy Doran, Catalent’s Vice President and General Manager of Nutritional Softgels commented, “At Catalent, we are dedicated to partnering with our customers at every level, to focus on supporting consumers’ needs for health and wellness throughout life.”

For more information on SupplySide West, visit

To arrange a meeting with any of the Catalent executives at the event, contact Richard Kerns at NEPR -

Media Contacts: 

Chris Halling
+44 (0)7580 041073 

Richard Kerns
+44 (0) 161 728 5880

OPTIBRIGHT™ is a trademark of Anklam Extrakt GmbH.

MaquiBright® is a registered trademark of Maqui New Life S.A. & Oryza Oil & Fat Chemical Co., Ltd.

About Catalent 

Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs over 11,000 people, including over 1,800 scientists, at more than 30 facilities across five continents, and in fiscal 2018 generated approximately $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit

More products. Better treatments. Reliably supplied.™